Aurobindo Pharma’s subsidiary Acrotech Biopharma has agreed to acquire seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in a deal valued at around $300m.
18 Jan 2019
17 Jan 2019
Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland China.
14 Jan 2019
Puma Biotechnology has entered into an exclusive license agreement with Knight Therapeutics that grants Knight the exclusive right to commercialize NERLYNX (neratinib) in Canada.
10 Jan 2019
Biopharmaceutical firm Eusa Pharma has purchased worldwide rights of Sylvant (siltuximab) from Janssen Sciences Ireland for $115m.
02 Jan 2019
Canadian healthcare company Nuvo Pharmaceuticals has completed the previously announced acquisition of a portfolio of more than 20 revenue-generating products from Aralez Pharmaceuticals.
27 Dec 2018
Opiant Pharmaceuticals has signed a licensing agreement with Sanofi for the development and commercialisation of drinabant across the globe for the treatment of acute cannabinoid overdose (ACO).
20 Dec 2018
Taisho Pharmaceutical has offered $1.6bn to acquire UPSA consumer health business from Bristol-Myers Squibb (BMS).
12 Dec 2018
Circassia Pharmaceuticals is set to exercise an option to purchase full US commercial rights of chronic obstructive pulmonary disease treatment, Tudorza (aclidinium), from AstraZeneca.
03 Dec 2018
Crown Laboratories, a privately held, fully integrated global skin care company, has acquired North American distribution rights of five OTC consumer brands from GlaxoSmithKline (GSK).
14 Nov 2018
AstraZeneca has agreed to offload the US rights of its respiratory drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) in a cash-cum-stock deal worth $1.5bn.